Vaccines and Microbicides Rebekah Webb, AVAC STOPAIDS All Members Meeting: Re-prioritising Prevention London, 12 th May 2016.

Slides:



Advertisements
Similar presentations
Telling Time; Telling the Truth Engaging communities as stakeholders (and partners) in HIV vaccine R&D Mitchell Warren AVAC 2 July 2013 IAS Symposia Session:
Advertisements

International Partnership for Microbicides New Science, New Hope: Giving Women Power Over AIDS The John Kevany Memorial Lecture Zeda Rosenberg, ScD, Chief.
Microbicides Envision a product that could save lives Your name here
State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
 Biomedical HIV Prevention strategies Wim Vandevelde European AIDS Treatment Group (EATG) European Community Advisory Board (ECAB) Conference on HIV Infection.
Prevention on the Line AVAC Report 2014/15 February 2015.
Use of Antivirals in Prevention Oral and Topical Prophylaxis
Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.
Innovation to Protect Women’s Reproductive Health in Kenya MULTIPURPOSE PREVENTION TECHNOLOGIES (MPTS) Meeting name Presenter Organization Date.
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Introduction to HIV New Prevention Technologies (NPTs)
Topical, Oral; Daily, Intermittent; Single, Combination agents; What do we need AND what will work? Patrick Ndase, Microbicide Trials Network & Dep’t of.
Microbicides: New Hope for Prevention of HIV and other STIs
Global Campaign for Microbicides Rebekah Webb, European Coordinator
Microbicides: Who, what, where, when and how Rebekah Webb Global Campaign for Microbicides © Salam Dahbor,
Cindra Feuer and Marc-André LeBlanc HRCF, 21 April 2010 ARV-based Prevention.
Microbicide research in Africa: Partnership in Action Salim S. Abdool Karim, MD, PhD Director: CAPRISA Pro Vice-Chancellor (Research): University of KwaZulu-Natal.
International Partnership for Microbicides The Search for Microbicides: A Promising New Prevention Tool for Women US Congress, Women’s Policy Inc. Zeda.
Multipurpose Prevention Technologies What are they & why do we need them? [Presenter name, degree, affiliation] [Event title] [Date]
XIX International AIDS Conference
Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.
International Partnership for Microbicides New Science, New Hope – Giving Women Power Over AIDS Women’s Policy, Inc. Briefing Zeda Rosenberg, ScD, Chief.
Microbicides: Science, research, and overview of the field Dr Kamini Walia, Indian Council of Medical Research, New Delhi Bindiya Patel, Global Campaign.
MDP301 An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5.
Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,
Global Campaign Europe: Making it better, stronger and more strategic Rebekah Webb, Coordinator Global Campaign for Microbicides.
International Partnership for Microbicides Tessa Mattholie, European Liaison Officer, Brussels.
Moving the Rectal Microbicide Agenda Forward; Results from a Scientific, Ethical, and Community Consultative Process Ian McGowan MD PhD FRCP University.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
When Will Women Have Choices? Sharon Hillier University of Pittsburgh School and Medicine Microbicide Trials Network IAS, Washington DC, July 26, 2012.
HIV Prevention : Why we need more options for women Wanjiku Kamau Consultant: International AIDS Vaccine Initiative Consultant: International Partnership.
AIDS 2012 Where are we, and where are we going? Mitchell Warren Executive Director, AVAC August 15, 2012.
The Microbicide Trials Network Group 3 Lindsay O. Bryant Danielle M. Campbell Alan D. Johnson Leroy Smith Jr. Kendra M. Taylor May 31, 2016.
Partnering to Promote Female-controlled HIV Prevention Methods Matthews J, Becker J, Massey C, Jacobsen J, Patel B Ibis Reproductive Health, International.
INVESTING TO END THE AIDS EPIDEMIC: A NEW ERA FOR HIV RESEARCH & DEVELOPMENT HIV VACCINES WORKING GROUP & MICROBICIDES RESOURCE TRACKING E. Donaldson 1,
Dr. Manuel ROMARÍS Poverty-related Diseases European Commission Research DG Microbicides BXL, 07 October 2005 HIV/AIDS Research in the Sixth Framework.
Welcome South Africa 4 Rectal Microbicides A Stakeholder Consultation on Rectal Microbicide Research and Advocacy Please sign in.
Working Synergistically: Two Possible Mechanisms.
A Jo Robinson, Terrence Higgins Trust in cooperation with the Global Campaign for Microbicides Topical.
IAS July 1 The Caprisa 004 result in context Sheena McCormack Clinical Scientist MRC Clinical Trials Unit.
Topical Microbicides: New Hope for Non-Condom Prevention of HIV and other STDs Your name here on behalf of the Global Campaign.
International Partnership for Microbicides Approach to HIV Treatment and Care in Future IPM Microbicide Trials Pam Norick, Chief of External Relations.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Advances in Biomedical HIV Prevention Interventions
New Prevention Technologies Workshop Module 2: NPTs in context
International Partnership for Microbicides ARV-Based Microbicides - Cause for Optimism Dr. Zeda Rosenberg, CEO Mexico City, 4 August 2008.
HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.
HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.
Microbicides: New Hope for Prevention of HIV and other STIs Your name here
HOPE End of Study: Plans and Timeline
Rectal Microbicides: Where We’re Heading
On behalf of The MTN-020/ASPIRE Study Team
UZ-UCSF Annual Research Day 8 April 2016
MULTIPURPOSE PREVENTION TECHNOLOGY (MPT) PRODUCT PIPELINE & THEIR POTENTIAL ACCEPTABILITY AMONG ADOLESCENT GIRLS & YOUNG WOMEN Barbara Friedland, Population.
Private sector involvement IPM-Tibotec case study
Setting the Stage for PrEP Where are we now, and where should we go?
PrEP Pre-Exposure Prophylaxis
Percolating HIV Px Pipeline
Creating a new era of RM research and development: Acceptability, Tolerability, and Adherence of Three Rectal Microbicide Delivery Forms among HIV Seronegative.
Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.
Microbicides: Who, what, where, when and how
Every Mother, Every Child: Closing the Gaps in HIV Management
José Bauermeister PhD, MPH University of Pennsylvania MTN BRWG Member
2025 AIDS targets Technical meeting on prevention
Overview of PrEP studies: UZCHS-CTRC experience
Innovation in HIV Prevention Research Workshop
Presentation transcript:

Vaccines and Microbicides Rebekah Webb, AVAC STOPAIDS All Members Meeting: Re-prioritising Prevention London, 12 th May 2016

“It’s not just about putting pills in peoples’ mouths!” - Dr Marie Laga, Be-PrEP-ared study

% of PLHIV know their status 90% of those PLHIV on treatment 90% of those PLHIV undetectable HIV Prevention

Why do we still need research? More options = more infections averted No epidemic has ever been ended without a vaccine Need for “women-friendlier” and people-friendlier options Microbicides and vaccines are more sophisticated (PrEP = a systemic drug) Constant learning and innovation – link to a cure?

Will we ever have a vaccine? Preventive and therapeutic vaccines Proof of concept 2009: RV144 Thailand Pox-Protein Public-Private Partnership (P5) Consortium (Gates, HVTN, NIAID, SAMRI +Pharma) HVTN 702 late-2016/early results in 6 yrs Two approaches: – PLWHIV Antibodies (Bnabs): passive immunisation (AMP) – T-cell responses (Louis Picker monkey study) Moving towards a cure?

ARV-Based Prevention Includes PrEP, microbicides (gels and rings), long-acting injectables (LAIs), films, etc. These products being explored in clinical trials to date incorporate a single ARV or a combination of two ARVs Work also focused on non-ARVs and dual-purpose products (with contraception—called multipurpose prevention technologies or MPTs)

Dapivirine Ring IPM Ring Study 1950 women South Africa and Uganda 31% protection DREAM OLE (not PEPFAR) MTN ASPIRE Study 2629 women Malawi, South Africa, Uganda, Zimbabwe 27% protection HOPE OLE Flexible ring of elastic silicone Inside vagina, ring releases dapivirine slowly over time Two Phase III trials of 4-week vaginal dapivirine ring Modest HIV protection found!

PDPs Prevention research is often led by product development partnerships (PDPs) Lack of Pharma interest in prevention Non-profit mission with pharmaceutical expertise Focus on access: availability, affordability, acceptability, and adopted into the local health system; end-user experience Particularly useful in European context to pool resources

EU Prevention Research Investment Investment focused on early treatment and vaccines No investment in PrEP Limited investment in microbicides

Advocacy Agenda Deliver what we have. Provide oral PrEP to those at substantial risk (WHO) Advocate for full funding of the DREAM OLE and related studies (MDP401) Broaden and sustain the pipeline. Research into LAIs, vaccines, vaginal and rectal microbicides, MPTs & Bnabs must also continue Advocate for properly funded social science/ behavioural research components in clinical trials

Recommended Reading EATG Position Paper on Prevention (October 2015) – n_Position_Paper_now_available n_Position_Paper_now_available EATG AVAC Prevention Summit report (2016) – AVAC PxWire Vol 9. No.2: Dapivirine Ring results – files/PxWire_Vol9_No2.pdf files/PxWire_Vol9_No2.pdf

Connect With Facebook.com/AVAC Youtube.com/AVAC Sign up for our Advocates Network and Weekly NewsDigests newsletters at: